Improved classification of breast cancer by analysis of genetic alterations and gene expression profiling
By H. Horlings. 2011
1,375 citations recorded by the source corpus.
View Paper: https://www.semanticscholar.org/paper/514c2fa43e8e3d4791166375fc11ce0658aa5cec
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- T. Junttila
- N. Hynes
- Gwen Macdonald
- Yan He
- M. Sliwkowski
- R. Akita
- Kathryn L. Parsons
- Gail D Lewis Phillips
Citations in the corpus
- Targeting PI3K/Akt signal transduction for cancer therapy (2021, background): “However, many types of cancer are always resistant to a single RTK inhibitor because PI3K is activated by multiple RTKs in cancer.(54) Therefore, understanding RTK signaling networks will facilitate a better comprehension of the PI3K pathway and further exploration of cancer therapies.”
- ERBB receptors: From oncogene discovery to basic science to mechanism-based cancer therapeutics (2014, background): “…discoveries linking constitutive activation of PI3K signaling and resistance to HER2 inhibitors was accomplished by Berns et al. Using a large-scale small interfering RNA genetic screen, they identified PTEN as the only gene whose knockdown conferred trastuzumab resistance (Berns et al., 2007).”
- Molecular biology in breast cancer: intrinsic subtypes and signaling pathways. (2012, result): “In addition, mutations in this pathway have been associated with resistance to anti-HER2 drugs.(71) These data, added to the results obtained in phase I clinical trials with mTOR inhibitors(72) have led researchers to change the strategy in the development of this type of targeted therapies.”
- Crosstalk between cancer cells and tumor associated macrophages is required for mesenchymal circulating tumor cell-mediated colorectal cancer metastasis (2019, methodology): “scored semiquantitatively based on staining intensity and distribution using the immunoreactive score (IRS) as described elsewhere [25, 26].”
- Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. (2009, background): “Activating PIK3CA mutations have also been suggested to confer trastuzumab resistance (Berns et al., 2007).”
- Drug Resistance in Cancer: An Overview (2014, unknown): “phosphatase and tensin homolog (PTEN) function [26,27].”
- ErbB receptors and signaling pathways in cancer. (2009, methodology): “Furthermore, using an unbiased RNAi screen on an ErbB2+ breast tumor cell line, loss of PTEN was found to confer trastuzumab resistance [56 ].”